- Home
- » Tags
- » Integrase inhibitor
Top View
- A Novel Endonuclease Inhibitor Exhibits Broad-Spectrum Anti- Influenza Virus Activity in Vitro
- Analyses of HIV-1 Integrase Sequences Prior to South African
- China Japan United States Europe
- Triumeq, INN-Dolutegravir, Abacavir, Lamivudine
- Monitoring and Avoiding Integrase Inhibitor Toxicity
- A New HIV Integrase Inhibitor
- Dolutegravir: a Next-Generation Integrase Inhibitor for Treatment of HIV Infection
- HIV Reservoirs During Suppressive Antiretroviral Therapy
- Drug Resistance of Human Immunodeficiency Virus and Overcoming It by Natural Products
- INTEGRASE INHIBITORS 22 October 2016, Glasgow, United Kingdom ABSTRACTS
- Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir Or Darunavir/Cobicistat
- Chemical Diversity and Activity Profiles of HIV-1 Reverse Transcriptase
- Reduction of CCR5 with Low-Dose Rapamycin Enhances the Antiviral Activity of Vicriviroc Against Both Sensitive and Drug-Resistant HIV-1
- Known Bioactive Library: Selleck Bioactive 10Mm, 3.33Mm, 1.11Mm
- The Network News
- Integrase Inhibitor Switches
- Key Pharmacology of Integrase Inhibitors: Pharmacokinetics
- Long-Term Efficacy and Safety of the HIV Integrase Inhibitor Raltegravir in Patients with Limited Treatment Options in a Phase II Study
- NORVIR Is Contraindicated in Patients with Known Hypersensitivity to NORVIR Safely and Effectively
- Integrase Strand Transfer Inhibitors Drug Resistance Mutations in Puerto Rico HIV-Positive Individuals
- Tea Polyphenols As Natural Products for Potential Future Management of HIV Infection
- HIV Integrase Inhibitors
- The Role of Therapeutic Drug Monitoring and Pharmacogenetic
- Parenteral Inhibitors of HIV Entry in Current Development The
- 2019 Update of the Drug Resistance Mutations in HIV-1
- Tea Catechin As Antiviral Agent Via Apoptosis Agonist and Triple
- Integrase Strand Transfer Inhibitors Are Effective Anti-HIV Drugs
- (12) United States Patent (10) Patent No.: US 9,708,342 B2 Carra Et Al
- Integrase Inhibitors in Second Line Treatment
- ( 12 ) Patent Application Publication
- Integrase Inhibitor (Ini) Resistance in Hiv- Positive Patients Undergoing Routine Testing
- An Overview of Human Immunodeficiency Virus-1 Antiretroviral Drugs: General Principles and Current Status
- HIV Integrase Inhibitor-Based Regimen Beats Market Leader
- With a Little Help from Good Friends – Boosters for the Prevention of Undesired Enzymatic Degradation of Anti-Infective Drugs
- Maraviroc Therapy and CCR5 Genotype Laura Dean, MD1 Created: March 18, 2015
- The Outlook for a Cure There Is a Formidable Arsenal of Drugs Available to Treat HIV
- Update on Recommended Antiretroviral Therapy for HIV
- Bioequivalence of a Dolutegravir, Abacavir, and Lamivudine Fixed-Dose Combination Tablet and the Effect of Food
- Drug Resistance Emerging During Therapy with Dolutegravir and Other Integrase Inhibitors
- The Pharmacokinetics of Dolutegravir Ritonavir-Boosted Protease
- Metal Chelators for the Inhibition of the Lymphocytic Choriomeningitis Virus Endonuclease Domain T
- Data Sheet for Triumeq
- Integrase Inhibitors to Treat Hiv/Aids
- Molecular Mechanisms of Retroviral Integrase Inhibition and the Evolution of Viral Resistance
- Dolutegravir Versus Raltegravir in Antiretroviral-Experienced
- Integrase Inhibitors on the Upswing for HIV
- 2 HIV Antiretroviral Therapy 11
- Q148N, a Novel Integrase Inhibitor Resistance Mutation Associated with Low-Level Reduction in Elvitegravir Susceptibility
- THE DOLUTEGRAVIR OPPORTUNITY Managing Supply Chain Risk for the Introduction of a New Antiretroviral (ARV) Medicine